RT Journal Article
SR Electronic
T1 Early detection of SARS-CoV-2 variants using traveler-based genomic surveillance at four US airports, September 2021- January 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.21.22272490
DO 10.1101/2022.03.21.22272490
A1 Renee D. Wegrzyn
A1 Grace D. Appiah
A1 Robert Morfino
A1 Scott R. Milford
A1 Allison Taylor Walker
A1 Ezra T. Ernst
A1 William W. Darrow
A1 Siayo Lisa Li
A1 Keith Robison
A1 Duncan MacCannell
A1 Dongjuan Dai
A1 Brintha P. Girinathan
A1 Allison L. Hicks
A1 Bryan Cosca
A1 Gabrielle Woronoff
A1 Alex M. Plocik
A1 Birgitte B. Simen
A1 Leah Moriarty
A1 Sarah Anne J. Guagliardo
A1 Martin S. Cetron
A1 Cindy R. Friedman
YR 2022
UL http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272490.abstract
AB We enrolled arriving international air travelers in SARS-CoV-2 genomic surveillance, using molecular testing of pooled nasal swabs, and sequencing positive samples for viral lineage. Traveler-based genomic surveillance provided early warning variant detection; we reported the first U.S. Omicron BA.2 and first BA.3 in North America, weeks before next reported detection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the U.S. Centers for Disease Control and Prevention (CDC)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors